TaurelFinance, decoded
Live
Loading market data…
TTaurel

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

MarketWatch· Nora Redmond· Jul 31, 2026 · 1:54 PM
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.

This is a summary. Read the complete story at MarketWatch below.

Read full article at MarketWatch

Related Stories

McDonald's Sits 21% Below Its High and 4% Above Its 52-Week Low. The Dividend Yields 2.7%.
marketsabout 1 hour ago

McDonald's Sits 21% Below Its High and 4% Above Its 52-Week Low. The Dividend Yields 2.7%.

Yahoo Finance

Inflation Could Wreck Your Retirement. Here's How to Avoid Letting That Happen.
marketsabout 1 hour ago

Inflation Could Wreck Your Retirement. Here's How to Avoid Letting That Happen.

Yahoo Finance

29-year-old fast-casual chain closes final location
marketsabout 1 hour ago

29-year-old fast-casual chain closes final location

Yahoo Finance